MedTrace Logo

Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

NCT02005198 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 98

Last updated 2017-01-05

No results posted yet for this study

Summary

This study is conducted in the United States of America (USA). The aim of the study is to assess the minimal important difference (MID) of the TRIM-AGHD.

Conditions

  • Growth Hormone Disorder
  • Adult Growth Hormone Deficiency

Interventions

OTHER

No treatment given

Subject will only fill out a questionnaire when entering the non-interventional study

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
23 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02005198 on ClinicalTrials.gov